CBD Activated Mast Cells in Lab Tests, Behaving Opposite to Synthetic Cannabinoids | Research

The takeaway

Unlike synthetic cannabinoids that suppressed mast cell activity, CBD actually triggered their activation through a calcium-dependent mechanism unrelated to known cannabinoid receptors.

Read this if you're interested in the complexity of how CBD affects the immune system beyond simple "anti-inflammatory" descriptions.

CBD activated mast cells while synthetic cannabinoids suppressed them

What the researchers found

Using a rat mast cell line (RBL-2H3), researchers found that CBD at concentrations of 3-10 micromolar increased the release of beta-hexosaminidase, a marker of mast cell activation. This occurred in both stimulated and unstimulated cells.

This effect was the opposite of what synthetic cannabinoids WIN 55,212-2 and CP 55,940 produced. Those compounds inhibited mast cell activation, while CBD enhanced it.

CBD's activating effect was associated with a robust increase in intracellular calcium levels. Importantly, this was not mediated through known G-protein coupled cannabinoid receptors or vanilloid VR1 receptors (tested using capsaicin, which had no effect on these cells). THC mimicked CBD's activating effect, suggesting natural cannabinoids interact with as-yet-unidentified receptors or ion channels.

Why it matters

CBD is widely described as "anti-inflammatory," but this study showed it could actually activate mast cells, key players in inflammatory responses. The finding that natural cannabinoids (CBD and THC) behaved opposite to synthetic cannabinoids suggests undiscovered receptors or mechanisms for cannabinoid action.

The numbers in context

CBD at 3-10 micromolar increased mast cell activation marker release. Calcium channel blockers clotrimazole and nitrendipine (10-30 micromolar) reduced the CBD effect. Capsaicin (vanilloid VR1 agonist) had no effect.

How the study worked

Researchers used the RBL-2H3 rat mast cell line to measure beta-hexosaminidase release (a marker of cell activation) and intracellular calcium levels in response to CBD, THC, and synthetic cannabinoids. They used pharmacological tools to probe which receptors and signaling pathways were involved.

What this study cannot tell us

The study used a single rat cell line, which may not represent how mast cells behave in living tissues or in humans. The concentrations used may not reflect physiologically achievable levels of CBD. In vitro mast cell activation may not translate to systemic inflammatory effects.

How to read the evidence

This is an in vitro cell line study, the most preliminary form of evidence. Results in isolated cells often don't predict what happens in whole organisms.

When this study was published

Published in 2007. Research has since identified additional cannabinoid-sensitive receptors (GPR55, GPR18, etc.) that may explain some of these findings.

The bigger picture

This study challenged the simple narrative that CBD is universally anti-inflammatory. It also suggested the existence of undiscovered cannabinoid interaction sites beyond CB1, CB2, and VR1 receptors, a prediction that has since been partially confirmed with the identification of additional cannabinoid-sensitive receptors.

Questions still open

What are the unidentified receptors through which CBD and THC activate mast cells? Does this mast cell activation occur in living animals or humans? Could this effect contribute to any reported adverse reactions to CBD?

Common questions

Does this mean CBD causes inflammation?

Not necessarily. Activating mast cells in a dish is very different from causing inflammation in a living body. CBD has shown anti-inflammatory effects in many other studies. This finding highlights that CBD's effects are more complex than simply "anti-inflammatory."

What are mast cells?

Mast cells are immune cells found throughout the body that play key roles in allergic reactions and inflammation. When activated, they release chemical signals like histamine that trigger inflammatory responses.

Read the original research

Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells.

Journal of leukocyte biology, 81(6), 1512-22

View on PubMed ↗

Citation

Giudice, Elda Del; Rinaldi, Luciano; Passarotto, Marzia; Facchinetti, Fabrizio; D'Arrigo, Antonello; Guiotto, Adriano; Carbonare, Maurizio Dalle; Battistin, Leontino; Leon, Alberta. (2007). Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells.. Journal of leukocyte biology, 81(6), 1512-22.